Targeted Brain Tumor Radiotherapy Using an Auger Emitter.

Published on Feb 17, 2020in Clinical Cancer Research10.107
· DOI :10.1158/1078-0432.CCR-19-2440
Giacomo Pirovano9
Estimated H-index: 9
(MSK: Memorial Sloan Kettering Cancer Center),
Stephen A. Jannetti6
Estimated H-index: 6
(MSK: Memorial Sloan Kettering Cancer Center)
+ 9 AuthorsThomas Reiner39
Estimated H-index: 39
(Cornell University)
Sources
Abstract
Purpose: Glioblastoma multiforme is a highly aggressive form of brain cancer whose location, tendency to infiltrate healthy surrounding tissue, and heterogeneity significantly limit survival, with scant progress having been made in recent decades. Experimental design: 123 I-MAPi (Iodine-123 Meitner-Auger PARP1 inhibitor) is a precise therapeutic tool composed of a PARP1 inhibitor radiolabeled with an Auger- and gamma-emitting iodine isotope. Here, the PARP inhibitor, which binds to the DNA repair enzyme PARP1, specifically targets cancer cells, sparing healthy tissue, and carries a radioactive payload within reach of the cancer cells9 DNA. Results: The high relative biological efficacy of Auger electrons within their short range of action is leveraged to inflict DNA damage and cell death with high precision. The gamma ray emission of 123 I-MAPi allows for the imaging of tumor progression and therapy response, and for patient dosimetry calculation. Here we demonstrated the efficacy and specificity of this small molecule radiotheranostic in a complex preclinical model. In vitro and in vivo studies demonstrate high tumor uptake and a prolonged survival in mice treated with 123 I-MAPi when compared to vehicle controls. Different methods of drug delivery were investigated to develop this technology for clinical applications, including convection enhanced delivery (CED) and intrathecal injection. Conclusions: Taken together, these results represent the first full characterization of an Auger-emitting PARP inhibitor which demonstrate a survival benefit in mouse models of GBM and confirm the high potential of 123 I-MAPi for clinical translation.
📖 Papers frequently viewed together
12 Authors (Giacomo Pirovano, ..., Thomas Reiner)
3 Citations
41 Citations
46 Citations
References56
Newest
#1Hwan Lee (UPenn: University of Pennsylvania)H-Index: 3
#2Aladdin Riad (UPenn: University of Pennsylvania)H-Index: 8
Last. Mehran Makvandi (UPenn: University of Pennsylvania)H-Index: 14
view all 10 authors...
: The currently available therapeutic radiopharmaceutical for high-risk neuroblastoma, 131I-MIBG, is ineffective at targeting micrometastases due to the low linear energy transfer (LET) properties of high-energy beta particles. In contrast, Auger radiation has high-LET properties with nanometer ranges in tissue, efficiently causing DNA damage when emitted in close proximity to DNA. The aim of this study was to evaluate the cytotoxicity of targeted Auger therapy in pre-clinical models of high-ris...
8 CitationsSource
#1Lukas M. Carter (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 10
#2Troy Crawford (URI: University of Rhode Island)H-Index: 4
Last. Jason S. Lewis (Cornell University)H-Index: 87
view all 10 authors...
: Mesh-type and voxel-based computational phantoms comprise the current state of the art for internal dose assessment via Monte Carlo simulations but excel in different aspects, with mesh-type phantoms offering advantages over their voxel counterparts in terms of their flexibility and realistic representation of detailed patient- or subject-specific anatomy. We have developed PARaDIM (pronounced "paradigm": Particle and Heavy Ion Transport Code System-Based Application for Radionuclide Dosimetry...
9 CitationsSource
#1Ute Hennrich (DKFZ: German Cancer Research Center)H-Index: 6
#2Klaus Kopka (DKFZ: German Cancer Research Center)H-Index: 56
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera® combines the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors. As a result, DNA single- and double-str...
52 CitationsSource
#1Javian Malcolm (University of Oxford)H-Index: 3
#2Nadia Falzone (University of Oxford)H-Index: 15
Last. Katherine A. Vallis (University of Oxford)H-Index: 37
view all 4 authors...
Compared to external beam radiotherapy, targeted radionuclide therapy (TRT) allows for systemic radiation treatment of metastatic lesions. Published work on recent strategies to improve patient management and response to TRT through individualising patient treatment, modifying treatment pharmacokinetics and increasing anticancer potency are discussed in this review, with a special focus on the application of clinically evaluated radiolabelled ligands and peptides in the treatment of neuroendocri...
16 CitationsSource
#1Junior Gonzales (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 4
#2Susanne Kossatz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 15
Last. Thomas Reiner (Cornell University)H-Index: 39
view all 10 authors...
The preclinical potential of many diagnostic and therapeutic small molecules is limited by their rapid washout kinetics and consequently modest pharmacological performances. In several cases, these could be improved by loading the small molecules into nanoparticulates, improving blood half-life, in vivo uptake and overall pharmacodynamics. In this study, we report a nanoemulsion (NE) encapsulated form of PARPi-FL. As a proof of concept, we used PARPi-FL, which is a fluorescently labeled sensor f...
10 CitationsSource
#1Bas M. Bavelaar (University of Oxford)H-Index: 2
#2B. Q. Lee (University of Oxford)H-Index: 11
Last. Katherine A. Vallis (University of Oxford)H-Index: 37
view all 5 authors...
The last decade has seen rapid growth in the use of theranostic radionuclides for the treatment and imaging of a wide range of cancers. Radionuclide therapy and imaging rely on a radiolabelled vector (pharmacon) to specifically target cancer cells. Radionuclides that emit β particles have thus far dominated the field of targeted radionuclide therapy (TRT), mainly because the longer range (μm-mm track length) of these particles offsets the heterogeneous expression of the targeting moiety. Shorter...
41 CitationsSource
#1Mark M. Souweidane (Cornell University)H-Index: 50
#2Kim Kramer (Cornell University)H-Index: 41
Last. Ira J. Dunkel (Cornell University)H-Index: 58
view all 15 authors...
Summary Background Diffuse intrinsic pontine glioma is one of the deadliest central nervous system tumours of childhood, with a median overall survival of less than 12 months. Convection-enhanced delivery has been proposed as a means to efficiently deliver therapeutic agents directly into the brainstem while minimising systemic exposure and associated toxic effects. We did this study to evaluate the safety of convection-enhanced delivery of a radioimmunotherapy agent targeting the glioma-associa...
110 CitationsSource
#1Stephen A. Jannetti (CUNY: City University of New York)H-Index: 6
#2Giuseppe Carlucci (NYU: New York University)H-Index: 27
Last. Thomas Reiner (Cornell University)H-Index: 39
view all 19 authors...
: The DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP-1) is overexpressed in glioblastoma, with overall low expression in healthy brain tissue. Paired with the availability of specific small molecule inhibitors, PARP-1 is a near-ideal target to develop novel radiotherapeutics to induce DNA damage and apoptosis in cancer cells, while sparing healthy brain tissue. Methods: We synthesized an 131I-labeled PARP-1 therapeutic and investigated its pharmacology in vitro and in vivo. A subcutaneous...
20 CitationsSource
#1Patrick L. Donabedian (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
#2Susanne Kossatz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 15
Last. Thomas Reiner (Cornell University)H-Index: 39
view all 9 authors...
Radiation injury can be indistinguishable from recurrent tumor on standard imaging. Current protocols for this differential diagnosis require one or more follow-up imaging studies, long dynamic acquisitions, or complex image post-processing; despite much research, the inability to confidently distinguish between these two entities continues to pose a significant dilemma for the treating clinician. Using mouse models of both glioblastoma and radiation necrosis, we tested the potential of poly(ADP...
8 CitationsSource
#1Komal Anjum (ZJU: Zhejiang University)H-Index: 10
#2Bibi Ibtesam Shagufta (Kohat University of Science and Technology)H-Index: 4
Last. Syed Shams-ul-Hassan (ZJU: Zhejiang University)H-Index: 1
view all 8 authors...
9 CitationsSource
Cited By28
Newest
#1Thomas C. Wilson (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
#2Giacomo Pirovano (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
Last. Naga Vara Kishore Pillarsetty (Cornell University)H-Index: 8
view all 12 authors...
Despite Auger electrons being highly appealing due to their short-range and high linear energy transfer to surrounding tissues, the progress in the field has been limited due to the challenge in delivering a therapeutic dose within the close proximity of cancer cell's DNA. Here, we demonstrate that the PARP inhibitor 123I-MAPi is a viable agent for the systemic administration and treatment of p53 mutant cancers. Significantly, minimal off-site toxicity was observed in mice administered with up t...
Source
#1Paula Demétrio De Souza França (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 6
#2Navjot Guru (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 4
Last. Elizabeth L. Jewell (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 22
view all 12 authors...
Despite efforts in prevention, cervical cancer still presents with a high worldwide incidence and remains a great problem in public health, especially in low-income countries. Screening programs, such as colposcopy with Papanicolaou testing, have greatly improved mortality rates. However, the agents currently used to delineate those lesions (topical application of acetic acid and/or Lugol's iodine) lack specificity and sometimes can lead to unnecessary biopsies or even cervical excisions. A tool...
1 CitationsSource
#1Ines M. Costa ('KCL': King's College London)
#2Jordan Cheng ('KCL': King's College London)
Last. Samantha Y.A. Terry ('KCL': King's College London)H-Index: 13
view all 5 authors...
Abstract In oncology, the holy grail of radiotherapy is specific radiation dose deposition in tumours with minimal healthy tissue toxicity. If used appropriately, injectable, systemic radionuclide therapies could meet these criteria, even for treatment of micrometastases and single circulating tumour cells. The clinical use of α and β- particle-emitting molecular radionuclide therapies is rising, however clinical translation of Auger electron-emitting radionuclides is hampered by uncertainty aro...
Source
#1Elise Verger (St Thomas' Hospital)H-Index: 1
#2Jordan Cheng (St Thomas' Hospital)
Last. Daniel R. Burnham (Francis Crick Institute)H-Index: 17
view all 11 authors...
Abstract null null Introduction null The biological consequences of absorbed radiation doses are ill-defined for radiopharmaceuticals, unlike for external beam radiotherapy (EBRT). A reliable assay that assesses the biological consequences of any radionuclide is much needed. Here, we evaluated the cell-free plasmid DNA assay to determine the relative biological effects of radionuclides such as Auger electron-emitting [67Ga]GaCl3 or [111In]InCl3 compared to EBRT. null null null Methods null Super...
Source
#1Giacomo Pirovano (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
#2Alvaro A. Ordonez (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 18
Last. Naga Vara Kishore Pillarsetty (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 8
view all 6 authors...
PURPOSE: Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus 2019 disease (COVID-19), poses a serious risk to humanity and represents a huge challenge for healthcare systems worldwide. Since the early days of the COVID-19 pandemic, it has been evident that adequate testing is an essential step in limiting and controlling the spread of SARS-CoV-2. Here, we present an accurate, inexpensive, scalable, portable, and rapid detection kit to directly dete...
Source
#1Dong ZhouH-Index: 23
#2Huaping ChenH-Index: 1
Last. Jinbin XuH-Index: 31
view all 8 authors...
Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical enzyme in the DNA repair process and the target of several FDA-approved inhibitors. Several of these inhibitors have been radiolabeled for non-invasive imaging of PARP-1 expression or targeted radiotherapy of PARP-1 expressing tumors. In particular, derivatives of olaparib and rucaparib, which have reduced trapping potency by PARP-1 compared to talazoparib, have been radiolabeled for these purposes. Here, we report the first radiosynthesis of...
Source
#1Pei PeiH-Index: 1
#2Teng Liu (Soochow University (Suzhou))H-Index: 43
Last. Kai Yang
view all 5 authors...
Radiation therapy (RT), including external beam radiotherapy (EBRT) and internal radioisotope therapy (RIT), has been an indispensable strategy for cancer therapy in clinical practice in recent years. Ionized atoms and free radicals emitted from the nucleus of radioisotopes can cleave a single strand of DNA, inducing the apoptosis of cancer cells. Thus far, nuclides used for RIT could be classified into three main types containing alpha (α), beta (β), and Auger particle emitters. In order to enh...
1 CitationsSource
#2Anne Sofie Nautrup Therkelsen (University of Southern Denmark)H-Index: 1
Last. Helge ThisgaardH-Index: 12
view all 5 authors...
Abstract Introduction Treatment of glioblastomas (GBM) using the Auger electron emitting compound [125I]5-Iodo-2′-deoxyuridine ([125I]I-UdR), combined with the thymidylate synthase inhibitor methotrexate (MTX) and concomitant chemotherapy with temozolomide (TMZ) has recently shown very promising therapeutic effects in vitro and in vivo in animals. The aim of the current study was to investigate if the therapeutic effects of this multimodal treatment strategy could be further increased by the thy...
Source
#1Elena Vagia (NU: Northwestern University)H-Index: 2
#2Massimo Cristofanilli (NU: Northwestern University)H-Index: 100
OPINION STATEMENT Inflammatory breast cancer (IBC) remains the most aggressive type of breast cancer. During the past decade, enormous progress has been made to refine diagnostic criteria and establish multimodality treatment strategies as keys for the improvement of survival outcomes. Multiple genomic studies enabled a better understanding of underlying tumor biology, which is responsible for the complex and aggressive nature of IBC. Despite these important achievements, outcomes for this subgr...
1 CitationsSource
#1Alex Rigby (St Thomas' Hospital)
#2Julia E. Blower (St Thomas' Hospital)H-Index: 4
Last. Vincenzo Abbate ('KCL': King's College London)H-Index: 17
view all 5 authors...
Abstract Introduction Thallium-201 is a radionuclide that has previously been used clinically for myocardial perfusion scintigraphy. Although in this role it has now been largely replaced by technetium-99 m radiopharmaceuticals, thallium-201 remains attractive in the context of molecular radionuclide therapy for cancer micrometastases or single circulating tumour cells. This is due to its Auger electron (AE) emissions, which are amongst the highest in total energy and number per decay for AE-emi...
Source